Doesn't sound like anything is going to happen until 2022
Key Focus Areas for FY22
•Achieve Australian regulatory approval for EuGeni and commence domestic sales.
•Continue to expand international Life Science distribution network and complete country level regulatory approvals and build sales
.•Develop US market entry strategy for EuGeni andprogress US regulatory approval.
•Progress Energy collaborations to commercial outcomes for AnteoX.
Quarterly Business Update
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $50.57M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.3¢ | 2.1¢ | $38.09K | 1.731M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1505316 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 676543 | 1 |
View Market Depth
| Last trade - 15.57pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.2¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.3¢ | 2.2¢ | 764931 | ||
| Last updated 15.55pm 03/05/2024 ? | |||||
| ADO (ASX) Chart |